Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 5/20 | 0.39 |
| ▸ | TNF | P01375 | 3/20 | 0.39 |
| ▸ | CIT | O14578 | 1/20 | 0.39 |
| ▸ | MUSK | O15146 | 1/20 | 0.39 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | STK10 | O94804 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.39 |
| ▸ | PRKCB | P05771 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6587531 | 0.96 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11KDR | |
| SCHEMBL6585102 | 0.81 | GSK3A (0.39) | MAPK14KDRSRCGSK3ASYK | |
| SCHEMBL14380430 | 0.80 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11KDR | |
| SCHEMBL6810815 | 0.79 | KDR (0.42) | MAPK14KDRRAF1BRAFGSK3A | |
| SCHEMBL5622491 | 0.78 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11KDR | |
| SCHEMBL6589214 | 0.77 | KDR (0.41) | MAPK14KDRSRCRAF1BRAF | |
| SCHEMBL5623931 | 0.77 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11KDR | |
| SCHEMBL6598212 | 0.77 | KDR (0.40) | MAPK14MAPK12KDRSRCLCK | |
| SCHEMBL6583664 | 0.77 | KDR (0.40) | MAPK14MAPK12KDRSRCRAF1 | |
| SCHEMBL5622991 | 0.76 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004534787-A | — | — | 2004-11-18 | — | — | JP | claimed |
| EP-1414810-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-05-06 | — | — | EP | claimed |
| US-20030100608-A1 | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-29 | — | — | US | claimed |
| WO-2002098869-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | claimed |
| US-6720321-B2 | REACTING THE ALDEHYDE WITH CARBETHOXYMETHYLENE TRIPHENYLYPHOSPHORANE TO FORM UNSATURATED ESTER, REACTING ESTER WITH DIAZOMETHANE IN PRESENCE OF PALLADIUM ACETATE TO FORM CYCLOPROPANE CABROXYLIC ESTER, HYDROLYSIS TO FORM ACID | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100608-A1 | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | MPO, NFKBIA, YBX1 | MAPK14 3283/4885MAPK13 3656/4885MAPK12 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.